Answers are grounded in this paper and cite their sources.
// Huaping Chen 1, * , Siyuan Chen 1, * , Shan Li 1, * , Zhijian Chen 1 , Xuan Zhu 1 , Meiyu Dai 1 , Lingxi Kong 1 , Xiaodan Lv 1 , Zhili Huang 1 and Xue Qin 1 1 Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, China * These authors contributed equally to this work and should be considered as co-first authors Correspondence to: Xue Qin, email: qinxue919@126.com Keywords: des-gamma-carboxyprothrombin, AFP, hepatocellular cancer, diagnosis, meta-analysis Received: June 22, 2017 Accepted: July 30, 2017 Published: August 07, 2017 ABSTRACT Controversies about the combination of des-gamma-carboxyprothrombin (DCP) and alpha-fetoprotein (AFP) for hepatocellular carcinoma diagnosing still exist. Hence, we performed this updated meta-analysis to estimate the diagnostic value of DCP , AFP and DCP + AFP in HCC. In addition, we conducted a validation study to analyze the performance of the candidate makers. After a systematic literature review, 27 studies from 20 articles were identified from four major databases. The pooled sensitivity and specificity were 69% and 89%, respectively, for DCP; for AFP, they were 65% and 88%, respectively; and they were 82% and 85%, respectively, for DCP + AFP. The values of the area under the curve (AUC) for DCP, AFP, DCP + AFP, respectively, were 0.88, 0.75, and 0.90. The validation study confirmed that the performance of DCP + AFP (sensitivity = 84%, specificity = 86%; AUC = 0.887) was higher than that of DCP (sensitivity = 76%, specificity = 92%; AUC = 0.843) or AFP (sensitivity = 73%, specificity = 92%; AUC = 0.837) alone.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: